Zafgen, Inc. (ZFGN) Reaches $8.38 After 9.00% Down Move; ZK International Group Company Limited OR (ZKIN) Shorts Increased By 6.25%

February 15, 2018 - By Lawrence Diaz

ZK International Group Company Limited OR (NASDAQ:ZKIN) had an increase of 6.25% in short interest. ZKIN’s SI was 3,400 shares in February as released by FINRA. Its up 6.25% from 3,200 shares previously. With 20,400 avg volume, 0 days are for ZK International Group Company Limited OR (NASDAQ:ZKIN)’s short sellers to cover ZKIN’s short positions. The stock decreased 1.66% or $0.1355 during the last trading session, reaching $8.0245. About 45,449 shares traded. ZK International Group Co., Ltd. (NASDAQ:ZKIN) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Zafgen, Inc. (NASDAQ:ZFGN) is a huge mover today! The stock decreased 5.95% or $0.53 during the last trading session, reaching $8.38. About 147,873 shares traded. Zafgen, Inc. (NASDAQ:ZFGN) has declined 36.39% since February 15, 2017 and is downtrending. It has underperformed by 53.09% the S&P500.The move comes after 6 months negative chart setup for the $230.36 million company. It was reported on Feb, 15 by Barchart.com. We have $7.63 PT which if reached, will make NASDAQ:ZFGN worth $20.73 million less.

ZK International Group Co., Ltd., together with its subsidiaries, designs, produces, and sells double-press thin-walled stainless steel, carbon steel, and single-press tubes and fittings in China. The company has market cap of $106.06 million. The firm offers steel strips, steel pipes, and light gauge stainless steel pipes, as well as pipe connections and fittings, such as couplings, adapters, unions, caps, plug pipes, elbows, three-way fittings, tees, cross, side-inlet elbows, wyes, reducers, bushings, couplings, pipe fasteners, and pipe flanges. It has a 15 P/E ratio. The Company’s products are used in a range of applications, including water and gas transmission within urban infrastructural development, residential housing development, food and beverage production, gas and oil exploitation, and agricultural irrigation.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The company has market cap of $230.36 million. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. It currently has negative earnings.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>